Discontinuation of phenytoin and carbamazepine in patients receiving felbamate
- PMID: 1904346
- DOI: 10.1111/j.1528-1157.1991.tb04669.x
Discontinuation of phenytoin and carbamazepine in patients receiving felbamate
Abstract
Five patients participated in a controlled discontinuation of phenytoin (PHT) and carbamazepine (CBZ) after a study in which all subjects had felbamate (FBM) added to both PHT and CBZ. Four subjects (three women and 1 man aged 23-36 years) completed the protocol. Mean total seizure frequency per day with PHT and CBZ was 1.33 +/- 0.93 (mean +/- SEM), decreasing to 0.87 +/- 0.71 with addition of FBM, and 0.82 +/- 0.78 after discontinuation of PHT. Only one subject tolerated discontinuation of CBZ; the other three had dosage reductions of 33, 54, and 63%. Toxicity attributable to FBM was not observed, and patients often described less severe seizures. Results from four refractory patients indicated that FBM was able to replace PHT and reduce the need for CBZ. In addition, as PHT dosages were reduced, FBM clearance decreased 21%. As the CBZ dosages were reduced. FBM clearance decreased an additional 16.5%.
Similar articles
-
Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate.Epilepsia. 1999 Aug;40(8):1122-8. doi: 10.1111/j.1528-1157.1999.tb00829.x. Epilepsia. 1999. PMID: 10448826 Clinical Trial.
-
Effect of felbamate on phenytoin and carbamazepine serum concentrations.Epilepsia. 1989 Mar-Apr;30(2):225-9. doi: 10.1111/j.1528-1157.1989.tb05458.x. Epilepsia. 1989. PMID: 2647472 Clinical Trial.
-
Felbamate: a clinical trial for complex partial seizures.Epilepsia. 1991 May-Jun;32(3):392-7. doi: 10.1111/j.1528-1157.1991.tb04668.x. Epilepsia. 1991. PMID: 2044501 Clinical Trial.
-
Antiepileptic drugs in development: prospects for the near future.Epilepsia. 1994;35 Suppl 4:S29-40. doi: 10.1111/j.1528-1157.1994.tb05953.x. Epilepsia. 1994. PMID: 8174517 Review.
-
Felbamate: successful development of a new compound for the treatment of epilepsy.Epilepsia. 1993;34 Suppl 7:S30-3. doi: 10.1111/j.1528-1157.1993.tb04592.x. Epilepsia. 1993. PMID: 8243376 Review.
Cited by
-
Clinically relevant drug interactions with antiepileptic drugs.Br J Clin Pharmacol. 2006 Mar;61(3):246-55. doi: 10.1111/j.1365-2125.2005.02529.x. Br J Clin Pharmacol. 2006. PMID: 16487217 Free PMC article. Review.
-
Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.Clin Pharmacokinet. 2013 Nov;52(11):927-66. doi: 10.1007/s40262-013-0087-0. Clin Pharmacokinet. 2013. PMID: 23784470 Review.
-
Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy.Drugs. 1993 Jun;45(6):1041-1065. doi: 10.2165/00003495-199345060-00008. Drugs. 1993. PMID: 7691493 Review.
-
Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?Clin Pharmacokinet. 2006;45(11):1061-75. doi: 10.2165/00003088-200645110-00002. Clin Pharmacokinet. 2006. PMID: 17048972 Review.
-
Organic carbamates in drug design and medicinal chemistry.J Med Chem. 2015 Apr 9;58(7):2895-940. doi: 10.1021/jm501371s. Epub 2015 Jan 7. J Med Chem. 2015. PMID: 25565044 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials